Effects of Ticagrelor, Prasugrel, or Clopidogrel on Endothelial Function and Other Vascular Biomarkers: A Randomized Crossover Study

The study sought to assess whether treatment with ticagrelor, as compared with prasugrel and clopidogrel, improves endothelium-dependent dilation throughout the course of the treatment and other vascular biomarkers, including systemic adenosine plasma levels. The in vivo off-target effects of ticagr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JACC. Cardiovascular interventions 2018-08, Vol.11 (16), p.1576-1586
Hauptverfasser: Ariotti, Sara, Ortega-Paz, Luis, van Leeuwen, Maarten, Brugaletta, Salvatore, Leonardi, Sergio, Akkerhuis, K Martijn, Rimoldi, Stefano F, Janssens, Gladys, Gianni, Umberto, van den Berge, Jan C, Karagiannis, Alexios, Windecker, Stephan, Valgimigli, Marco
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1586
container_issue 16
container_start_page 1576
container_title JACC. Cardiovascular interventions
container_volume 11
creator Ariotti, Sara
Ortega-Paz, Luis
van Leeuwen, Maarten
Brugaletta, Salvatore
Leonardi, Sergio
Akkerhuis, K Martijn
Rimoldi, Stefano F
Janssens, Gladys
Gianni, Umberto
van den Berge, Jan C
Karagiannis, Alexios
Windecker, Stephan
Valgimigli, Marco
description The study sought to assess whether treatment with ticagrelor, as compared with prasugrel and clopidogrel, improves endothelium-dependent dilation throughout the course of the treatment and other vascular biomarkers, including systemic adenosine plasma levels. The in vivo off-target effects of ticagrelor in post-acute coronary syndrome (ACS) patients remain poorly characterized. Fifty-four stable post-ACS patients were sequentially exposed to each of the 3 oral P2Y inhibitors following a 3-period balanced Latin square crossover design with 4 weeks per treatment in 5 European centers. The primary endpoint was the assessment of endothelial function with pulse amplitude tonometry and expressed as reactive hyperemia index at treatment steady state. Secondary endpoints included reactive hyperemia index after loading or before maintenance regimen, systemic adenosine plasma levels, a wide set of vascular biomarkers, and ticagrelor or AR-C124910XX plasma levels throughout each ticagrelor period. In 9 patients, the evaluation of endothelial function was performed simultaneously by pulse amplitude tonometry and flow-mediated dilation. Reactive hyperemia index did not differ after ticagrelor (1.970 ± 0.535) as compared with prasugrel (2.007 ± 0.640; p = 0.557) or clopidogrel (2.072 ± 0.646; p = 0.685), nor did systemic adenosine plasma levels or vascular biomarkers at any time points. P2Y platelet reactivity units were lower after ticagrelor as compared with clopidogrel at all time points and after maintenance dose as compared with prasugrel. Flow-mediated dilation did not differ after the maintenance dose of ticagrelor as compared with clopidogrel and prasugrel. Ticagrelor did not improve endothelial function or increased systemic adenosine plasma levels as compared with prasugrel and clopidogrel in stabilized patients who suffered from an ACS. (Hunting for the Off-Target Properties of Ticagrelor on Endothelial Function in Humans [HI-TECH]; NCT02587260).
doi_str_mv 10.1016/j.jcin.2018.04.022
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_2046013423</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2046013423</sourcerecordid><originalsourceid>FETCH-LOGICAL-p211t-1c41b8a189cf6aa863da001d6b5856b9add7c19912b5999afc4937d4bdab47673</originalsourceid><addsrcrecordid>eNo1kEFLwzAAhYMgbk7_gAfJ0cNak7RNG2-zbCoMJjq9ljRJNTNtatIK8-7_8Lf4y-xwnh7v8fHgPQDOMAoxwvRyE26EbkKCcBaiOESEHIAxzlIapBQlI3Ds_QYhilhKjsCIsAwlGJMx-JpXlRKdh7aCay34i1PGuim8d9z3OzOF1sHc2FZLu_PQNnDeSNu9KqO5gYu-EZ0eQt7In-_VEDv4zL3oDXfwWtuauzfl_BWcwYcBsbX-VBLmznpvPwb2sevl9gQcVtx4dbrXCXhazNf5bbBc3dzls2XQEoy7AIsYlxnHGRMV5TyjkeQIYUnLJEtoybiUqcCMYVImjDFeiZhFqYxLycs4pWk0ARd_va2z773yXVFrL5QxvFG29wVBMUU4ikk0oOd7tC9rJYvW6WHKtvi_LvoFHutyNQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2046013423</pqid></control><display><type>article</type><title>Effects of Ticagrelor, Prasugrel, or Clopidogrel on Endothelial Function and Other Vascular Biomarkers: A Randomized Crossover Study</title><source>Elsevier ScienceDirect Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Ariotti, Sara ; Ortega-Paz, Luis ; van Leeuwen, Maarten ; Brugaletta, Salvatore ; Leonardi, Sergio ; Akkerhuis, K Martijn ; Rimoldi, Stefano F ; Janssens, Gladys ; Gianni, Umberto ; van den Berge, Jan C ; Karagiannis, Alexios ; Windecker, Stephan ; Valgimigli, Marco</creator><creatorcontrib>Ariotti, Sara ; Ortega-Paz, Luis ; van Leeuwen, Maarten ; Brugaletta, Salvatore ; Leonardi, Sergio ; Akkerhuis, K Martijn ; Rimoldi, Stefano F ; Janssens, Gladys ; Gianni, Umberto ; van den Berge, Jan C ; Karagiannis, Alexios ; Windecker, Stephan ; Valgimigli, Marco ; HI-TECH Investigators</creatorcontrib><description>The study sought to assess whether treatment with ticagrelor, as compared with prasugrel and clopidogrel, improves endothelium-dependent dilation throughout the course of the treatment and other vascular biomarkers, including systemic adenosine plasma levels. The in vivo off-target effects of ticagrelor in post-acute coronary syndrome (ACS) patients remain poorly characterized. Fifty-four stable post-ACS patients were sequentially exposed to each of the 3 oral P2Y inhibitors following a 3-period balanced Latin square crossover design with 4 weeks per treatment in 5 European centers. The primary endpoint was the assessment of endothelial function with pulse amplitude tonometry and expressed as reactive hyperemia index at treatment steady state. Secondary endpoints included reactive hyperemia index after loading or before maintenance regimen, systemic adenosine plasma levels, a wide set of vascular biomarkers, and ticagrelor or AR-C124910XX plasma levels throughout each ticagrelor period. In 9 patients, the evaluation of endothelial function was performed simultaneously by pulse amplitude tonometry and flow-mediated dilation. Reactive hyperemia index did not differ after ticagrelor (1.970 ± 0.535) as compared with prasugrel (2.007 ± 0.640; p = 0.557) or clopidogrel (2.072 ± 0.646; p = 0.685), nor did systemic adenosine plasma levels or vascular biomarkers at any time points. P2Y platelet reactivity units were lower after ticagrelor as compared with clopidogrel at all time points and after maintenance dose as compared with prasugrel. Flow-mediated dilation did not differ after the maintenance dose of ticagrelor as compared with clopidogrel and prasugrel. Ticagrelor did not improve endothelial function or increased systemic adenosine plasma levels as compared with prasugrel and clopidogrel in stabilized patients who suffered from an ACS. (Hunting for the Off-Target Properties of Ticagrelor on Endothelial Function in Humans [HI-TECH]; NCT02587260).</description><identifier>EISSN: 1876-7605</identifier><identifier>DOI: 10.1016/j.jcin.2018.04.022</identifier><identifier>PMID: 29805112</identifier><language>eng</language><publisher>United States</publisher><ispartof>JACC. Cardiovascular interventions, 2018-08, Vol.11 (16), p.1576-1586</ispartof><rights>Copyright © 2018 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29805112$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ariotti, Sara</creatorcontrib><creatorcontrib>Ortega-Paz, Luis</creatorcontrib><creatorcontrib>van Leeuwen, Maarten</creatorcontrib><creatorcontrib>Brugaletta, Salvatore</creatorcontrib><creatorcontrib>Leonardi, Sergio</creatorcontrib><creatorcontrib>Akkerhuis, K Martijn</creatorcontrib><creatorcontrib>Rimoldi, Stefano F</creatorcontrib><creatorcontrib>Janssens, Gladys</creatorcontrib><creatorcontrib>Gianni, Umberto</creatorcontrib><creatorcontrib>van den Berge, Jan C</creatorcontrib><creatorcontrib>Karagiannis, Alexios</creatorcontrib><creatorcontrib>Windecker, Stephan</creatorcontrib><creatorcontrib>Valgimigli, Marco</creatorcontrib><creatorcontrib>HI-TECH Investigators</creatorcontrib><title>Effects of Ticagrelor, Prasugrel, or Clopidogrel on Endothelial Function and Other Vascular Biomarkers: A Randomized Crossover Study</title><title>JACC. Cardiovascular interventions</title><addtitle>JACC Cardiovasc Interv</addtitle><description>The study sought to assess whether treatment with ticagrelor, as compared with prasugrel and clopidogrel, improves endothelium-dependent dilation throughout the course of the treatment and other vascular biomarkers, including systemic adenosine plasma levels. The in vivo off-target effects of ticagrelor in post-acute coronary syndrome (ACS) patients remain poorly characterized. Fifty-four stable post-ACS patients were sequentially exposed to each of the 3 oral P2Y inhibitors following a 3-period balanced Latin square crossover design with 4 weeks per treatment in 5 European centers. The primary endpoint was the assessment of endothelial function with pulse amplitude tonometry and expressed as reactive hyperemia index at treatment steady state. Secondary endpoints included reactive hyperemia index after loading or before maintenance regimen, systemic adenosine plasma levels, a wide set of vascular biomarkers, and ticagrelor or AR-C124910XX plasma levels throughout each ticagrelor period. In 9 patients, the evaluation of endothelial function was performed simultaneously by pulse amplitude tonometry and flow-mediated dilation. Reactive hyperemia index did not differ after ticagrelor (1.970 ± 0.535) as compared with prasugrel (2.007 ± 0.640; p = 0.557) or clopidogrel (2.072 ± 0.646; p = 0.685), nor did systemic adenosine plasma levels or vascular biomarkers at any time points. P2Y platelet reactivity units were lower after ticagrelor as compared with clopidogrel at all time points and after maintenance dose as compared with prasugrel. Flow-mediated dilation did not differ after the maintenance dose of ticagrelor as compared with clopidogrel and prasugrel. Ticagrelor did not improve endothelial function or increased systemic adenosine plasma levels as compared with prasugrel and clopidogrel in stabilized patients who suffered from an ACS. (Hunting for the Off-Target Properties of Ticagrelor on Endothelial Function in Humans [HI-TECH]; NCT02587260).</description><issn>1876-7605</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNo1kEFLwzAAhYMgbk7_gAfJ0cNak7RNG2-zbCoMJjq9ljRJNTNtatIK8-7_8Lf4y-xwnh7v8fHgPQDOMAoxwvRyE26EbkKCcBaiOESEHIAxzlIapBQlI3Ds_QYhilhKjsCIsAwlGJMx-JpXlRKdh7aCay34i1PGuim8d9z3OzOF1sHc2FZLu_PQNnDeSNu9KqO5gYu-EZ0eQt7In-_VEDv4zL3oDXfwWtuauzfl_BWcwYcBsbX-VBLmznpvPwb2sevl9gQcVtx4dbrXCXhazNf5bbBc3dzls2XQEoy7AIsYlxnHGRMV5TyjkeQIYUnLJEtoybiUqcCMYVImjDFeiZhFqYxLycs4pWk0ARd_va2z773yXVFrL5QxvFG29wVBMUU4ikk0oOd7tC9rJYvW6WHKtvi_LvoFHutyNQ</recordid><startdate>20180827</startdate><enddate>20180827</enddate><creator>Ariotti, Sara</creator><creator>Ortega-Paz, Luis</creator><creator>van Leeuwen, Maarten</creator><creator>Brugaletta, Salvatore</creator><creator>Leonardi, Sergio</creator><creator>Akkerhuis, K Martijn</creator><creator>Rimoldi, Stefano F</creator><creator>Janssens, Gladys</creator><creator>Gianni, Umberto</creator><creator>van den Berge, Jan C</creator><creator>Karagiannis, Alexios</creator><creator>Windecker, Stephan</creator><creator>Valgimigli, Marco</creator><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20180827</creationdate><title>Effects of Ticagrelor, Prasugrel, or Clopidogrel on Endothelial Function and Other Vascular Biomarkers: A Randomized Crossover Study</title><author>Ariotti, Sara ; Ortega-Paz, Luis ; van Leeuwen, Maarten ; Brugaletta, Salvatore ; Leonardi, Sergio ; Akkerhuis, K Martijn ; Rimoldi, Stefano F ; Janssens, Gladys ; Gianni, Umberto ; van den Berge, Jan C ; Karagiannis, Alexios ; Windecker, Stephan ; Valgimigli, Marco</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p211t-1c41b8a189cf6aa863da001d6b5856b9add7c19912b5999afc4937d4bdab47673</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ariotti, Sara</creatorcontrib><creatorcontrib>Ortega-Paz, Luis</creatorcontrib><creatorcontrib>van Leeuwen, Maarten</creatorcontrib><creatorcontrib>Brugaletta, Salvatore</creatorcontrib><creatorcontrib>Leonardi, Sergio</creatorcontrib><creatorcontrib>Akkerhuis, K Martijn</creatorcontrib><creatorcontrib>Rimoldi, Stefano F</creatorcontrib><creatorcontrib>Janssens, Gladys</creatorcontrib><creatorcontrib>Gianni, Umberto</creatorcontrib><creatorcontrib>van den Berge, Jan C</creatorcontrib><creatorcontrib>Karagiannis, Alexios</creatorcontrib><creatorcontrib>Windecker, Stephan</creatorcontrib><creatorcontrib>Valgimigli, Marco</creatorcontrib><creatorcontrib>HI-TECH Investigators</creatorcontrib><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>JACC. Cardiovascular interventions</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ariotti, Sara</au><au>Ortega-Paz, Luis</au><au>van Leeuwen, Maarten</au><au>Brugaletta, Salvatore</au><au>Leonardi, Sergio</au><au>Akkerhuis, K Martijn</au><au>Rimoldi, Stefano F</au><au>Janssens, Gladys</au><au>Gianni, Umberto</au><au>van den Berge, Jan C</au><au>Karagiannis, Alexios</au><au>Windecker, Stephan</au><au>Valgimigli, Marco</au><aucorp>HI-TECH Investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of Ticagrelor, Prasugrel, or Clopidogrel on Endothelial Function and Other Vascular Biomarkers: A Randomized Crossover Study</atitle><jtitle>JACC. Cardiovascular interventions</jtitle><addtitle>JACC Cardiovasc Interv</addtitle><date>2018-08-27</date><risdate>2018</risdate><volume>11</volume><issue>16</issue><spage>1576</spage><epage>1586</epage><pages>1576-1586</pages><eissn>1876-7605</eissn><abstract>The study sought to assess whether treatment with ticagrelor, as compared with prasugrel and clopidogrel, improves endothelium-dependent dilation throughout the course of the treatment and other vascular biomarkers, including systemic adenosine plasma levels. The in vivo off-target effects of ticagrelor in post-acute coronary syndrome (ACS) patients remain poorly characterized. Fifty-four stable post-ACS patients were sequentially exposed to each of the 3 oral P2Y inhibitors following a 3-period balanced Latin square crossover design with 4 weeks per treatment in 5 European centers. The primary endpoint was the assessment of endothelial function with pulse amplitude tonometry and expressed as reactive hyperemia index at treatment steady state. Secondary endpoints included reactive hyperemia index after loading or before maintenance regimen, systemic adenosine plasma levels, a wide set of vascular biomarkers, and ticagrelor or AR-C124910XX plasma levels throughout each ticagrelor period. In 9 patients, the evaluation of endothelial function was performed simultaneously by pulse amplitude tonometry and flow-mediated dilation. Reactive hyperemia index did not differ after ticagrelor (1.970 ± 0.535) as compared with prasugrel (2.007 ± 0.640; p = 0.557) or clopidogrel (2.072 ± 0.646; p = 0.685), nor did systemic adenosine plasma levels or vascular biomarkers at any time points. P2Y platelet reactivity units were lower after ticagrelor as compared with clopidogrel at all time points and after maintenance dose as compared with prasugrel. Flow-mediated dilation did not differ after the maintenance dose of ticagrelor as compared with clopidogrel and prasugrel. Ticagrelor did not improve endothelial function or increased systemic adenosine plasma levels as compared with prasugrel and clopidogrel in stabilized patients who suffered from an ACS. (Hunting for the Off-Target Properties of Ticagrelor on Endothelial Function in Humans [HI-TECH]; NCT02587260).</abstract><cop>United States</cop><pmid>29805112</pmid><doi>10.1016/j.jcin.2018.04.022</doi><tpages>11</tpages></addata></record>
fulltext fulltext
identifier EISSN: 1876-7605
ispartof JACC. Cardiovascular interventions, 2018-08, Vol.11 (16), p.1576-1586
issn 1876-7605
language eng
recordid cdi_proquest_miscellaneous_2046013423
source Elsevier ScienceDirect Journals; EZB-FREE-00999 freely available EZB journals
title Effects of Ticagrelor, Prasugrel, or Clopidogrel on Endothelial Function and Other Vascular Biomarkers: A Randomized Crossover Study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T05%3A30%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20Ticagrelor,%20Prasugrel,%20or%20Clopidogrel%20on%20Endothelial%20Function%20and%C2%A0Other%20Vascular%20Biomarkers:%20A%20Randomized%20Crossover%20Study&rft.jtitle=JACC.%20Cardiovascular%20interventions&rft.au=Ariotti,%20Sara&rft.aucorp=HI-TECH%20Investigators&rft.date=2018-08-27&rft.volume=11&rft.issue=16&rft.spage=1576&rft.epage=1586&rft.pages=1576-1586&rft.eissn=1876-7605&rft_id=info:doi/10.1016/j.jcin.2018.04.022&rft_dat=%3Cproquest_pubme%3E2046013423%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2046013423&rft_id=info:pmid/29805112&rfr_iscdi=true